Last 12 months
Inside the activity.
2 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2019 Filed Mar 12, 2019 00:38 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000055 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,724 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 49,825 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:30 UTC |
DOUBLEDAY RICHARDEVP Chief Commercial Officer
|
GrantCommon Stock | 16,365 | $0.00 | $16.37 |
DisclosureSEC source: 0001093557-19-000051 · wf-form4_155235063585618.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,381 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:27 UTC |
MOY JEFFREYSVP Operations
|
GrantCommon Stock | 11,714 | $0.00 | $11.71 |
DisclosureSEC source: 0001093557-19-000049 · wf-form4_155235045068337.xml · nonDerivative · entry 1 MOY JEFFREY · CIK 0001446422 · SVP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,610 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 39,070 unvested restricted stock units, 11,714 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 20,062 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 7,294 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:35 UTC |
Leach Jacob StevenEVP Chief Technology Officer
|
GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000053 · wf-form4_155235090240114.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · EVP Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,638 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 42,760 unvested restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 20,062 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 7,711 of which were granted on March 8, 2017 and shall vest through March 8, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 00:25 UTC |
Abbey DonaldEVP Quality and Regulatory Aff
|
GrantCommon Stock | 14,987 | $0.00 | $14.99 |
DisclosureSEC source: 0001093557-19-000047 · wf-form4_155235030701474.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality and Regulatory Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,076 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 68,158 restricted stock units, 14,987 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 18,333 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 333 | $153.80 | $51,216.30 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 6 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,737 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $153.69 to $153.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 147 | $151.78 | $22,311.66 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 5 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,070 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 154 | $144.06 | $22,185.96 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 4 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,217 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $144.04 to $144.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 93 | $142.64 | $13,265.52 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,371 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 115 | $141.47 | $16,268.48 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,464 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:58 UTC |
Pacelli Steven RobertEVP Strategy and Corporate Dev
|
SaleCommon Stock | 825 | $140.50 | $115,909.45 |
DisclosureSEC source: 0001093557-19-000044 · wf-form4_155122907767740.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP Strategy and Corporate Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,579 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.11 to $140.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:01 UTC |
FOLETTA MARK GDirector
|
SaleCommon Stock | 200 | $149.52 | $29,904.00 |
DisclosureSEC source: 0001093557-19-000034 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,095 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $149.41 to $149.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 22:01 UTC |
FOLETTA MARK GDirector
|
SaleCommon Stock | 800 | $148.52 | $118,819.04 |
DisclosureSEC source: 0001093557-19-000034 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,295 F1 · shares: On December 13, 2018, Mr. Foletta adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Foletta. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.94 to $148.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC |
SAYER KEVIN RDirector · President, CEO and Chairman
|
SaleCommon Stock | 800 | $150.42 | $120,339.52 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $149.83 to $150.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC |
SAYER KEVIN RDirector · President, CEO and Chairman
|
SaleCommon Stock | 3,100 | $149.02 | $461,968.82 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,637 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $148.58 to $149.47. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:23 UTC |
SAYER KEVIN RDirector · President, CEO and Chairman
|
SaleCommon Stock | 2,100 | $148.14 | $311,091.27 |
DisclosureSEC source: 0001093557-19-000021 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,737 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.58 to $148.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 21:46 UTC |
Murphy Patrick MichaelSVP Legal Affairs
|
SaleCommon Stock | 400 | $142.76 | $57,104.00 |
DisclosureSEC source: 0001093557-19-000019 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · SVP Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,308 F1 · shares: On June 15, 2018, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 24,998 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 5,681 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 2,500 of which were granted on March 8, 2016 shall vest through March 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:24 UTC |
Murphy Patrick MichaelSVP Legal Affairs
|
SaleCommon Stock | 400 | $142.76 | $57,104.00 |
DisclosureSEC source: 0000899243-19-003373 · doc4.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · SVP Legal Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,308 F1 · shares: On June 15, 2018, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 24,998 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 5,681 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 2,500 of which were granted on March 8, 2016 shall vest through March 8, 2019. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 22:46 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 3,114 | $149.74 | $466,302.50 |
DisclosureSEC source: 0001093557-19-000014 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,404 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.50 to $150.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 22:30 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 1,024 | $141.39 | $144,781.31 |
DisclosureSEC source: 0001093557-19-000009 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $141.30 to $141.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 22:30 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 4,976 | $140.91 | $701,148.75 |
DisclosureSEC source: 0001093557-19-000009 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,861 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $140.35 to $141.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC |
KAHN BARBARADirector
|
SaleCommon Stock | 5,343 | $142.83 | $763,154.58 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 5 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,817 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.51 to $143.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC |
KAHN BARBARADirector
|
SaleCommon Stock | 3,558 | $142.07 | $505,470.83 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 4 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 22,160 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.51 to $142.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC |
KAHN BARBARADirector
|
SaleCommon Stock | 1,730 | $141.16 | $244,201.44 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 3 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 25,718 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.51 to $141.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| January 10, 2019 Filed Jan 15, 2019 02:42 UTC |
Murphy Patrick MichaelSVP, GC & Chief Compliance Off
|
SaleCommon Stock | 400 | $138.75 | $55,500.00 |
DisclosureSEC source: 0001093557-19-000007 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,708 F1 · shares: On June 15, 2018, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 24,998 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 5,681 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 2,500 of which were granted on March 8, 2016 shall vest through March 8, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC |
ALTMAN STEVEN RDirector
|
SaleCommon Stock | 2,500 | $117.04 | $292,593.25 |
DisclosureSEC source: 0001093557-19-000005 · edgardoc.xml · nonDerivative · entry 1 ALTMAN STEVEN R · CIK 0001191307 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 52,855 F1 · shares: On August 6, 2018, Mr. Altman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Altman. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $117.01 to $117.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC |
SKYLER JAY SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,806 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-19-000004 · edgardoc.xml · derivative · entry 4 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 0 Underlying: Common Stock · 25,806 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC |
SKYLER JAY SDirector
|
Exercise / conversionCommon Stock | 25,806 | $4.58 | $118,191.48 |
DisclosureSEC source: 0001093557-19-000004 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 52,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 310 | $110.61 | $34,287.74 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,112 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $110.40 to $111.08. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 700 | $109.57 | $76,699.98 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 14,422 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.38 to $109.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:33 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 500 | $108.23 | $54,113.10 |
DisclosureSEC source: 0001093557-18-000258 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,122 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.59. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 377 | $110.97 | $41,835.69 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,518 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,960 | $109.57 | $214,759.16 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,895 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $109.09 to $109.87. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 01:22 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 777 | $108.24 | $84,105.35 |
DisclosureSEC source: 0001093557-18-000257 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,855 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $107.97 to $108.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:34 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 4,373 | $121.38 | $530,782.50 |
DisclosureSEC source: 0001093557-18-000254 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.01 to $121.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:34 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 627 | $120.23 | $75,384.34 |
DisclosureSEC source: 0001093557-18-000254 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,478 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $120.00 to $120.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:09 UTC |
Murphy Patrick MichaelSVP, GC & Chief Compliance Off
|
SaleCommon Stock | 400 | $121.90 | $48,760.00 |
DisclosureSEC source: 0001093557-18-000252 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · SVP, GC & Chief Compliance Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,108 F1 · shares: On June 15, 2018, Mr. Murphy adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Murphy. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 24,998 unvested restricted stock units, 16,817 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 5,681 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 2,500 of which were granted on March 8, 2016 shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,162 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · derivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,162 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 1,012 | $123.18 | $124,658.67 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,837 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $123.08 to $123.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 2,560 | $122.41 | $313,379.33 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,849 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $122.01 to $122.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 4,988 | $121.64 | $606,753.29 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,409 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.01 to $121.97. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
SaleCommon Stock | 2,602 | $120.39 | $313,249.84 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,397 F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.00 to $120.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 02:08 UTC |
SAYER KEVIN RDirector · President, CEO & Chairman
|
Exercise / conversionCommon Stock | 11,162 | $4.58 | $51,121.96 |
DisclosureSEC source: 0001093557-18-000251 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 10, 2018, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 136,185 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 40,640 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 15,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,236 | $122.00 | $150,794.97 |
DisclosureSEC source: 0001093557-18-000244 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 15,622 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $122.00 to $122.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 500 | $119.74 | $59,869.00 |
DisclosureSEC source: 0001093557-18-000244 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,858 F1 · shares: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.64 to $120.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 700 | $122.04 | $85,425.97 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 3 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,632 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $122.03 to $122.05. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,814 | $121.71 | $220,788.65 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,332 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $121.03 to $122.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 23:27 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 600 | $119.82 | $71,890.02 |
DisclosureSEC source: 0001093557-18-000243 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 F1 · shares: On June 11, 2018, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.64 to $120.21. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 58,591 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 13,755 of which were granted on March 8, 2017 and shall vest through March 8, 2020, and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 1,498 | $144.43 | $216,358.54 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 4 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,105 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $144.23 to $144.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 22:14 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 1,502 | $143.88 | $216,100.55 |
DisclosureSEC source: 0001093557-18-000240 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,603 F1 · shares: On June 14, 2018, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $143.10 to $144.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.